NCT02878889Unknown2 期
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 53
- 试验地点
- 2
- 主要终点
- Objective response rate
研究概览
简要总结
A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all proven to have locoregional recurrence after curative treatment and unsuitability for further local treatment, distant metastases at presentation or acquired metastases after curative treatment. the presence of at least one measurable disease, which was defined as lesion that could be measured at least 20 mm in one dimension by conventional computed tomography (CT) or at least 10 mm by spiral CT scan; KPS≥70, and a life expectancy of at least 6 months.
排除标准
- •other malignancy prior to study entry; bone-only metastasis;previous radiotherapy within 4 weeks; previous exposure to gemcitabine;patients with any active, non-controlled infection or other severe systemic diseases, such as congestive heart failure, angina pectoris, respiratory insufficiency and arrhythmia were all rejected at enrollment. Other exclusion criteria included concurrent treatment with other investigational drugs, hypersensitivity to platinum compounds,and current pregnancy or breastfeeding.
研究组 & 干预措施
Arm 1
Experimental
S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
干预措施: S-1 (Drug)
结局指标
主要结局
Objective response rate
时间窗: through study completion, an average of 1 year
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
2 期
Maintenance Chemotherapy With S-1, Locally Advanced Esophageal Cancer Receiving Definitive CCRTLocally Advanced Unresectable Esophageal CancerNCT06598917China Medical University Hospital60
已完成
2 期
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic CancerPancreas NeoplasmsNCT01693419Hallym University Medical Center37
招募中
2 期
PhaseII study of maintenance S-1 after chemotherapy with platinium+pemetrexed in advanced nonsquamous NSCLC.on Squamous Non Small Cell Lung CancerJPRN-UMIN000009275Kansai Medical University22
已完成
2 期
Phase II study of gemcitabine/S-1 combination therapy in patients with non-resectable advanced biliary tract cancernon-resectable biliary tract cancer or recurrent biliary tract cancer post surgical treatmentJPRN-UMIN000000792Kyoto University Hospital25
已完成
1 期
Phase I/II study of gemcitabine/cisplatin/S-1(GCS) combination therapy for patients with advanced biliary tract cancerPatients with advanced biliary tract cancer that was not amenable to potentially curative surgery or that had recurred after surgeryJPRN-UMIN000004468Kansai Hepatobiliary Oncology Group55